BioSapien is a biotech startup focusing on developing a 3D printed drug delivery platform to provide FDA approved drugs.
BioSapien is a pre-clinical biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications with reduced systemic side effects. The applications for this technology are currently under investigation for pancreatic cancer and lung cancer. The intended pipeline of indications is expected to expand into other cancers such as colorectal, breast, and stomach cancers. BioSapien's 3D-printed MediChip delivers FDA-approved toxic high-dose systemic therapies in a localized slow-release biodegradable mesh which is able to target tissues while improving patients' quality of care and life.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 1, 2022 | Series A | $35M | 3 | — | — | Detail |
Nov 11, 2021 | Grant | $256K | 1 | National Science Foundation | — | Detail |
Nov 11, 2021 | Seed | $1.80M | 11 | SOSV | — | Detail |
Jan 1, 2021 | Series Unknown | — | 1 | — | — | Detail |
Jan 20, 2020 | Convertable Note | — | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |
IndieBio | — | Series A |
North West Quadrant Ventures ( NWQ Ventures) | — | Series A |
SOSV | — | Series A |
Cedas Foundation | — | Seed |
Harbr | — | Seed |
Beni VC | — | Seed |
George and Saul | — | Seed |
Hikma Ventures | — | Seed |
Infinity Capital | — | Seed |